Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.

Key Inclusion Criteria:

* Participants aged ≥ 2 years and \< 18 years
* Confirmed diagnosis somatostatin receptor-positive (SSTR-positive) disease.
* Tumor which is relapsed or is refractory to at least one line of previous therapy
* Positive SSTR protein expression confirmed by immunohistochemistry of a tumor histology sample
* Radioactivity uptake within the primary tumor or metastatic tumor sites measured by locally available SRIs ( 111In-based, 99mTc-based, or 68Ga-based SSTR single-photon emission computed tomography (SPECT)/ computed tomography (CT) or positron emission tomography (PET)/CT imaging, which is higher than the liver uptake)
* Participants must have recovered from the acute treatment related toxicities (defined as ≤ grade 1 if not defined in eligibility criteria, excluding alopecia, stable treated electrolyte abnormalities on replacement and stable treated hypothyroidism) of all prior treatment modality prior to entering this trial
* In case of sequential treatment followed by SoC or prior therapy, washout period applies before starting targeted RPT

Screening Consent Participant/legal guardian is willing to sign a screening consent. The screening consent is to be obtained according to institutional guidelines. Assent, when appropriate, will be obtained according to institutional guidelines.

Key Exclusion Criteria:

* Known hypersensitivity to Lutetium Lu 177 Edotreotide, DOTA/Edotreotide, or excipients
* Previous history of acute leukemia unless in remission for at least two years
* Extensive bone/bone marrow involvement as per Investigator's judgement unless peripheral blood stem cells (PBSC) are available at a minimum of 2.5x106 CD34+ cells/kg
* Patients who have received previous systemic targeted RPT
* Previous treatment with metaiodobenzyl guanidine (MIBG) if the predicted overall exposure is expected to exceed 2 Gy (gray) to the bone marrow or 23 Gy to the kidney.
* Previous treatment with external beam radiation therapy (EBRT) if the predicted overall exposure is expected to exceed more than 2 Gy to the bone marrow or 23 Gy to the kidney.
* Previous treatment with oncologic immune vaccine or CAR-T cell therapy
* Bulky disease in the CNS
* Presence of severe renal, hepatic, electrolyte, cardiovascular, or hematological dysfunction
* Participants who have received a live-attenuated vaccine up to four weeks prior to enrolment
* Pregnant or breastfeeding women.
* Other known malignancies.
* Serious non-malignant disease.